Clinical Trials

Breast Neoplasms

NCT05415215 2026-02-10

ProHer

346 enrolled 20 charts

Breast Neoplasms, Patient Preference, Inflammatory Breast Neoplasms

NCT01494662 2026-01-23

HKI-272 for HER2-Positive Breast Cancer and Brain Metastases

140 enrolled 32 charts

Phase 3 Active not recruiting

Breast Neoplasms

NCT03975647 2025-12-10

A Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer

466 enrolled 17 charts

Phase 2 Active not recruiting

HER2-positive Breast Cancer

NCT04439110 2025-11-21

Testing Ado-Trastuzumab Emtansine as a Potential Targeted Treatment in Cancers With HER2 Genetic Changes (MATCH-Subprotocol Q)

38 enrolled 10 charts

LymphoidOther hematologic neoplasmPlasma cell

Lymphoma, Multiple Myeloma, Hematologic Neoplasms

NCT03529110 2025-10-21

DS-8201a Versus T-DM1 for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive, Unresectable and/or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane [DESTINY-Breast03]

Phase 3 Active not recruiting

524 enrolled 11 charts 1 FDA

Breast Neoplasms

NCT04740918 2025-08-08

KATE3

Phase 3 Terminated

96 enrolled 16 charts

Breast Neoplasms

NCT01772472 2025-07-22

A Study of Trastuzumab Emtansine Versus Trastuzumab as Adjuvant Therapy in Patients With HER2-Positive Breast Cancer Who Have Residual Tumor in the Breast or Axillary Lymph Nodes Following Preoperative Therapy (KATHERINE)

1,486 enrolled 37 charts 1 FDA

Phase 2 Active not recruiting

Breast Neoplasms

NCT02326974 2025-03-05

T-DM1+Pertuzumab in Pre-OP Early-Stage HER2+ BRCA

164 enrolled 19 charts

Breast Neoplasms

NCT03032107 2025-01-27

A Study Of Pembrolizumab In Combination With Trastuzumab-DM1

20 enrolled 14 charts

Breast Neoplasms

NCT03726879 2024-11-05

IMpassion050

454 enrolled 28 charts

Breast Neoplasms

NCT03530696 2024-08-13

T-DM1

55 enrolled 19 charts

Breast Neoplasms

NCT01120184 2024-03-04

A Study of Trastuzumab Emtansine (T-DM1) Plus Pertuzumab/Pertuzumab Placebo Versus Trastuzumab [Herceptin] Plus a Taxane in Participants With Metastatic Breast Cancer (MARIANNE)

1,095 enrolled 46 charts

Breast Neoplasms

NCT03190967 2023-10-11

T-DM1 Alone Versus T-DM1 and Metronomic Temozolomide in Secondary Prevention of HER2-Positive Breast Cancer Brain Metastases Following Stereotactic Radiosurgery

12 enrolled 16 charts

BreastCNS

Brain Neoplasms, Breast Neoplasms

NCT03364348 2022-10-19

4-1BB Agonist Monoclonal Antibody PF-05082566 With Trastuzumab Emtansine or Trastuzumab in Treating Patients With Advanced HER2-Positive Breast Cancer

18 enrolled 17 charts

Breast Neoplasms

NCT01702571 2022-04-04

A Study of Trastuzumab Emtansine in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer Who Have Received Prior Anti-HER2 And Chemotherapy-based Treatment

2,185 enrolled 20 charts

Breast Neoplasms

NCT02562378 2022-02-23

THELMA

15 enrolled 39 charts

Breast Neoplasms

NCT02452554 2022-01-13

Lorvotuzumab Mertansine in Treating Younger Patients With Relapsed or Refractory Wilms Tumor, Rhabdomyosarcoma, Neuroblastoma, Pleuropulmonary Blastoma, Malignant Peripheral Nerve Sheath Tumor, or Synovial Sarcoma

62 enrolled 15 charts

CNSGenitourinarySarcoma

Pleuropulmonary blastoma, Wilms Tumor, Neuroblastoma, Rhabdomyosarcoma, Sarcoma, Synovial, Neurofibrosarcoma

NCT04296942 2022-01-11

BN-Brachyury, Entinostat, Adotrastuzumab Emtansine and M7824 in Advanced Stage Breast Cancer (BrEAsT)

Phase 1 Terminated

1 enrolled 10 charts

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04298918 2021-11-08

A Study Evaluating the Safety and Efficacy of Venetoclax in Combination With Trastuzumab Emtansine in Patients With Previously Treated HER2-Positive Locally Advanced or Metastatic Breast Cancer

1 enrolled

Breast Neoplasms

NCT02658734 2021-04-02

A Study of Trastuzumab Emtansine in Indian Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Unresectable Locally Advanced or Metastatic Breast Cancer Who Have Received Prior Treatment With Trastuzumab and a Taxane

Phase 4 Completed

70 enrolled 18 charts

Breast Neoplasms

NCT02924883 2021-02-17

KATE2

202 enrolled 21 charts

Breast Neoplasms

NCT02038010 2020-06-29

BYL719 + T-DM1 in HER2(+) Metastatic Breast Cancer Pts Who Progress on Prior Trastuzumab & Taxane Tx

17 enrolled 17 charts

Breast Neoplasms

NCT02318901 2019-10-21

PembroMab

16 enrolled 6 charts

BreastGastrointestinal

Breast Neoplasms, Esophageal Neoplasms, Stomach Neoplasms, Colorectal Neoplasms

NCT02999672 2019-08-28

KAMELEON

GastrointestinalGenitourinary

20 enrolled 14 charts

Urinary Bladder Neoplasms, Pancreatic Neoplasms, Cholangiocarcinoma

NCT02289833 2019-08-07

A Study of Trastuzumab Emtansine in Participants With Human Epidermal Growth Factor Receptor (HER)2 Immunohistochemistry (IHC)-Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

49 enrolled 22 charts

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT02658084 2019-04-17

Vinorelbine With Trastuzumab Emtansine in Pre-Treated HER2-Positive Metastatic Breast Cancer

2 enrolled 7 charts

Breast Neoplasms

NCT01641939 2017-05-12

A Study of Trastuzumab Emtansine Versus Taxane in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Gastric Cancer

Phase 2/3 Terminated

415 enrolled 25 charts

Gastrointestinal

Stomach Neoplasms

NCT00934856 2017-04-06

A Study of Trastuzumab Emtansine (T-DM1) in Combination With Docetaxel, and Potentially Pertuzumab, in Participants With Advanced Breast Cancer

Phase 1/2 Completed

98 enrolled 40 charts

Breast Neoplasms

NCT00679211 2017-03-31

A Study of Trastuzumab-Mcc-DM1 Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer

110 enrolled 12 charts

Breast Neoplasms

NCT02144012 2017-03-07

A Study to Evaluate the Efficacy and Safety of Trastuzumab Emtansine Versus the Combination of Trastuzumab Plus Docetaxel in Patients With HER2-positive Breast Cancer

Phase 3 Terminated

49 enrolled 16 charts

Breast Neoplasms

NCT00829166 2016-10-31

EMILIA

991 enrolled 26 charts

Breast Neoplasms

NCT01419197 2016-10-12

TH3RESA

602 enrolled 15 charts

Breast Neoplasms

NCT00951665 2016-06-24

A Study of Trastuzumab Emtansine, Paclitaxel, and Pertuzumab in Patients With HER2-Positive, Locally Advanced or Metastatic Breast Cancer

Phase 1/2 Completed

107 enrolled 31 charts

Breast Neoplasms

NCT00932373 2015-08-26

A Study of Trastuzumab-MCC-DM1 Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer Who Have Previously Received a Trastuzumab-Containing Regimen

54 enrolled 25 charts

Breast Neoplasms

NCT01196052 2014-10-06

A Study of Trastuzumab Emtansine (T-DM1) Sequentially With Anthracycline-based Chemotherapy, as Adjuvant or Neoadjuvant Therapy for Patients With Early Stage Herceptin (HER)2-positive Breast Cancer

153 enrolled 11 charts

Breast Neoplasms

NCT00679341 2014-01-09

A Study of the Efficacy and Safety of Trastuzumab Emtansine (Trastuzumab-MCC-DM1) vs. Trastuzumab (Herceptin®) and Docetaxel (Taxotere®) in Patients With Metastatic HER2-positive Breast Cancer Who Have Not Received Prior Chemotherapy for Metastatic Disease

137 enrolled 13 charts

Breast Neoplasms

NCT00875979 2013-12-24

A Study of Trastuzumab Emtansine (Trastuzumab-MCC-DM1, T-DM1) in Combination With Pertuzumab Administered to Patients With Human Epidermal Growth Factor Receptor-2 (HER2)-Positive Locally Advanced or Metastatic Breast Cancer Who Have Previously Received Trastuzumab

Phase 1/2 Completed

67 enrolled 9 charts

Breast Neoplasms

NCT00943670 2013-05-27

Corrected QT Interval Effects of Trastuzumab Emtansine (T-DM1) in Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Locally Advanced or Metastatic Breast Cancer and the Safety and Tolerability of Combined T-DM1 and Pertuzumab in Patients With Early Disease Progression

51 enrolled 27 charts

Breast Neoplasms

NCT00509769 2013-04-02

A Study of Trastuzumab Emtansine (Trastuzumab-MCC-DM1) Administered Intravenously to Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer

112 enrolled 10 charts